Description

Melanotan I Acetate

Melanotan I Acetate is a synthetic peptide analogue of alpha-Melanocyte-stimulating hormone used in controlled pharmaceutical research, analytical development, peptide characterization, and qualified drug-development programs. It is also known as Afamelanotide Acetate. The peptide should not be confused with unapproved consumer tanning products marketed under similar terminology. Material suitability depends on its confirmed sequence, acetate content, peptide purity, analytical profile, intended use, and applicable regulatory requirements. Melanotan I Acetate is
• A synthetic alpha-melanocyte-stimulating hormone analogue
• Also identified as Afamelanotide Acetate
• A peptide material for controlled pharmaceutical and analytical programs
• Suitable for identity testing, peptide characterization, formulation research, and qualified development activities
• Requires careful control of peptide purity, sequence identity, related peptides, residual solvents, water, and counterion content
• Supported by technical documentation for supplier qualification and quality review
Melanotan I Acetate is a Melanocortin peptide related to the naturally occurring alpha-Melanocyte-stimulating hormone. Reference databases identify Melanotan I Acetate under molecular formula C₈₀H₁₁₅N₂₁O₂₁. The exact molecular weight and assay basis should be confirmed from the individual product specification because peptide materials may be reported according to acetate, anhydrous, or peptide-content conventions.
The pharmaceutical form of Afamelanotide is used in SCENESSE, a prescription subcutaneous implant approved in the United States to increase pain-free light exposure in adults with erythropoietic protoporphyria. The approved implant contains 16 mg of Afamelanotide and must be administered by a trained healthcare professional. In the European Union, SCENESSE is authorized for the prevention of phototoxicity in adults with erythropoietic protoporphyria and remains subject to additional monitoring.
Melanotan I Acetate may be evaluated in peptide analytical programs, receptor-binding research, formulation development, stability studies, impurity profiling, and controlled pharmaceutical research. Pharmaceutical suitability cannot be inferred from the peptide name alone. Development teams must assess sequence confirmation, peptide content, chromatographic purity, related peptides, acetate content, residual solvents, water content, elemental impurities, microbial controls, bacterial endotoxins, sterility status where applicable, and stability under the proposed processing and storage conditions.
For organizations looking to purchase Melanotan I Acetate for legitimate research or qualified pharmaceutical development, supplier evaluation should focus on identity, analytical transparency, traceability, and intended-use controls. A qualified supplier should provide an unambiguous peptide sequence, current specification, lot-specific Certificate of Analysis, purity method, mass confirmation, counterion information, and appropriate safety documentation. Customers should also confirm whether the supplied material is intended for analytical research, nonclinical work, process development, or qualified pharmaceutical manufacturing.
CarboMer approaches Melanotan I Acetate sourcing with a regulation-first and manufacturing-centered perspective. Research teams benefit from a supplier capable of supporting peptide identity review, analytical method development, stability assessment, and repeat sourcing. Quality professionals require traceable lot records, clearly defined acceptance criteria, and controlled change communication. Procurement teams need confidence that the supplied material matches the intended grade and is supported by documentation appropriate to the development stage.
Melanotan I Acetate should not be marketed, supplied, or represented as a general cosmetic tanning ingredient or as a consumer-use injectable product. The approved afamelanotide product has a specific prescription indication, dosage form, dose, manufacturing process, and regulated administration pathway. Approval of SCENESSE does not establish that separately sourced Melanotan I Acetate is approved for direct administration, compounding, cosmetic use, or tanning purposes.
The material is supported by standard technical documentation, including a Certificate of Analysis, Safety Data Sheet, and related product information where applicable. Available documentation may include peptide sequence confirmation, chromatographic purity, mass-spectrometric identity, acetate or counterion content, water content, residual solvent information, storage conditions, and retest or expiration data. Exact documentation should be confirmed for the individual grade before purchase.
The material should be handled by trained personnel in controlled laboratory or manufacturing environments. Storage and handling must follow the product label, Certificate of Analysis, Safety Data Sheet, and applicable internal procedures. Peptide materials commonly require protection from moisture, light, contamination, repeated temperature cycling, and conditions that could promote degradation.
The material is packaged in appropriate containers selected to protect peptide quality during storage, handling, and transportation. Packaging configuration, order quantity, availability, lead time, and temperature-control requirements may be discussed according to analytical, research, and qualified pharmaceutical-development needs.
As with all CarboMer products, customers receive responsive technical communication and documentation support intended to advance material qualification, analytical evaluation, formulation research, regulatory review, and controlled supply planning.